Trial Profile

PRospEctiVe charactErization of Asthma Patients Treated With DupilumAb in reaL World Setting

Status: Active, no longer recruiting

Phase of Trial: Phase IV

Latest Information Update: 08 May 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Dupilumab (Primary)
Indications Asthma
Focus Therapeutic Use
Acronyms REVEAL
Sponsors Sanofi

Most Recent Events

01 May 2025 According to a Sanofi media release, data from this study will be presented at the American Thoracic Society (ATS) International Conference in San Francisco, CA, US from May 18 to 21, 2025.
29 May 2024 Planned End Date changed from 21 Dec 2026 to 1 Jul 2026.
29 May 2024 Planned primary completion date changed from 21 Dec 2026 to 1 Jul 2026.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com